RT Journal Article
SR Electronic
T1 Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.17.23293358
DO 10.1101/2023.08.17.23293358
A1 Dharan, Nila J.
A1 Sasson, Sarah C.
A1 Ahlenstiel, Golo
A1 Andersen, Christopher R.
A1 Bloch, Mark
A1 Buckland, Griselda
A1 Hamad, Nada
A1 Han, Win Min
A1 Kelleher, Anthony D.
A1 Long, Georgina V.
A1 Matthews, Gail V.
A1 Mina, Michael M.
A1 Papot, Emmanuelle
A1 Petoumenos, Kathy
A1 Swaminathan, Sanjay
A1 Withers, Barbara
A1 Yun, James
A1 Polizzotto, Mark N.
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/08/21/2023.08.17.23293358.abstract
AB People with immunocompromising conditions are at increased risk of SARS-CoV-2 infection and mortality, however early in the pandemic it was challenging to collate data on this heterogenous population. We conducted a registry study of immunocompromised individuals with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection from March – October 2020 in Sydney, Australia to understand clinical and laboratory outcomes in this population prior to the emergence of the Delta variant. 27 participants were enrolled into the study including people with a haematologic oncologic conditions (n=12), secondary immunosuppression (N=8) and those with primary or acquired immunodeficiency (i.e. HIV; N=7). All participants had symptomatic COVID-19 with the most common features being cough (64%), fever (52%) and headache (40%). Five patients demonstrated delayed SARS-CoV-2 clearance lasting three weeks to three months. The mortality rate in this study was 7% compared to 1.3% in the state of New South Wales Australia during the same period. This study provides data from the first eight months of the pandemic on COVID-19 outcomes in at-risk patient groups.Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: NJD has received research support through the Gilead Australia Fellowship for an unrelated project. GVL is consultant advisor to Agenus, Amgen, Array Biopharma, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics, Regeneron, unrelated to this study. GVM has received research funding from Gilead, Abbvie, Janssen and ViiV. ADK is an advisor to Merck and Aegros unrelated to this study. All other authors have declared that no competing interests exist.Funding StatementThis work was supported by an Unrestricted Scientific Grant from Gilead Sciences (https://www.gilead.com), awarded to M.N.P. (no salary funding was received). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the St Vincent's Hospital Human Research Ethics Committee and granted a waiver of the need for individual consent for data collection as per the National Statement on Ethical Conduct in Human ResearchI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets from this study are available from the corresponding author upon reasonable request.